Network pharmacology found that NSCLC tissues exhibited a high expression of SDC4, and further study of the interaction between the compounds and the target confirmed that the four compounds of JOEI (linoleic acid, OA, palmitic acid, and stearic acid) showed relatively high potential for binding to the active sites of five targets (FABP4, ABCB1, LDLR, PTGS2, and SDC4), which further verified that the mechanism of JOEI against NSCLC involves multiple targets and signaling pathways [25]. Here, FABP4 is linked to non-small cell lung carcinoma.